Vorapaxar utilization and cost trends in US public insurance programs

Abstract

Keywords

anti-thrombotic therapy arterial thrombosis economic analysis peripheral artery disease (PAD)pharmacotherapy

Get full access to this article

View all access options for this article.

References

Morrow

Paolasso

Ophuis

AJO

, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404–1413.

Qamar

Olin

Beckman

, et al. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial. Vasc Med 2020; 25: 124–132.

Gornik

Aronow

Goodney

, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2024; 149: e1313–e1410.

Uslu-Biçak

Nalçaci

Sözer

. Targeting PAR1 activation in JAK2V617F-driven philadelphia-negative myeloproliferative neoplasms: Unraveling its role in thrombosis and disease progression. Neoplasia 2025; 63: 101153.

Tsai

Alaiti

Banerjee

, et al. No benefit of vorapaxar on walking performance in patients with intermittent claudication. Vasc Med 2021; 27: 33–38.

Freedman

Berg

Scirica

, et al. Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial. Clin Cardiol 2022; 45: 831–838.

Centers for Medicare & Medicaid Services.Medicare & Medicaid Spending by Drug, https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/ (accessed Jan 8, 2026).

Tricoci

Hudson

Widimsky

, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20–33.

European Medicines Agency. Zontivity: EPAR – Summary for the public, https://www.ema.europa.eu/en/medicines/human/EPAR/zontivity (2017, (accessed Jan 8, 2026).

10.

Aralez acquires United States and Canadian rights to ZONTIVITY from Merck, https://www.americanpharmaceuticalreview.com/1315-News/191089-Aralez-Acquires-United-States-and-Canadian-Rights-to-ZONTIVITY-from-Merck/ (2016, accessed Jan 8, 2026).